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Abstract
Background: Asthmatics exhibit reduced airway dilation at maximal inspiration, likely due to structural differences
in airway walls and/or functional differences in airway smooth muscle, factors that may also increase airway
responsiveness to bronchoconstricting stimuli. The goal of this study was to test the hypothesis that the minimal
airway resistance achievable during a maximal inspiration (Rmin) is abnormally elevated in subjects with airway
hyperresponsiveness.
Methods: The Rmin was measured in 34 nonasthmatic and 35 asthmatic subjects using forced oscillations at 8 Hz. Rmin
and spirometric indices were measured before and after bronchodilation (albuterol) and bronchoconstriction
(methacholine). A preliminary study of 84 healthy subjects first established height dependence of baseline Rmin values.
Results: Asthmatics had a higher baseline Rmin % predicted than nonasthmatic subjects (134 ± 33 vs. 109 ± 19 %
predicted, p = 0.0004). Sensitivity-specificity analysis using receiver operating characteristic curves indicated that
baseline Rmin was able to identify subjects with airway hyperresponsiveness (PC20 < 16 mg/mL) better than most
spirometric indices (Area under curve = 0.85, 0.78, and 0.87 for Rmin % predicted, FEV1 % predicted, and FEF25-75 %
predicted, respectively). Also, 80% of the subjects with baseline Rmin < 100% predicted did not have airway
hyperresponsiveness while 100% of subjects with Rmin > 145% predicted had hyperresponsive airways, regardless
of clinical classification as asthmatic or nonasthmatic.
Conclusions: These findings suggest that baseline Rmin, a measurement that is easier to perform than spirometry,
performs as well as or better than standard spirometric indices in distinguishing subjects with airway
hyperresponsiveness from those without hyperresponsive airways. The relationship of baseline Rmin to asthma and
airway hyperresponsiveness likely reflects a causal relation between conditions that stiffen airway walls and
hyperresponsiveness. In conjunction with symptom history, Rmin could provide a clinically useful tool for assessing
asthma and monitoring response to treatment.
Background
Structural alterations in asthma include inflammation,
increased airway smooth muscle mass, and increased air-
way wall thickening [1]. These are not easily assessed in
patients, so clinicians rely on functional measurements
such as spirometry and tests of airway hyperresponsiveness
to assess the presence and control of asthma. Another
characteristic of asthma is higher airway resistance at
maximal inspiration compared to nonasthmatics. Jensen
and co-workers [2] used the minimum resistance
achieved at maximum inspiration (Rmin) as representing
the maximum airway dilation achievable (averaged over
the entire lung) by a subject. They showed that Rmin was
abnormally high (i.e., less ability to dilate the airway tree)
in asthmatic versus nonasthmatic subjects [2]. Salome
and co-workers confirmed the reduced ability of asth-
matics to dilate after deep inspiration and also showed
that the magnitude of dilation was negatively correlated
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workers [4] showed that respiratory system resistance
(Rrs) measured noninvasively by forced oscillation at
maximal inspiration represented the same Rmin as in the
Jensen study because the chest wall does not contribute
to Rrs at maximum inspiration. These studies attributed
the reduced dilation seen in asthmatics at maximum
inspiration to increased stiffness of airway smooth muscle
(ASM), reflecting structural characteristics such as hyper-
trophy and a more contractile state of ASM that may be
associated with airway hyperresponsiveness, which is a
defining characteristic of asthma.
The goal of this study was to test the hypothesis that
the minimal airway resistance achievable during a maxi-
mal inspiration (Rmin) is abnormally elevated in subjects
with airway hyperresponsiveness. To test this hypothesis,
we measured Rrs in nonasthmatic and asthmatic adults
during tidal breathing and at maximal inspiration at
baseline, following albuterol-induced bronchodilation,
and following methacholine-induced bronchoconstric-
tion. Because airway resistance is related to height, we
examined the relationship of Rmin to height in nonasth-
matic volunteers so that Rmin c o u l db ea n a l y z e da sa
percent of the predicted value. In addition, we compared
Rmin to spirometric indices in terms of their relationship
to methacholine airway responsiveness. If Rmin measured
by forced oscillation accurately reflects airway hyperre-
sponsiveness and structural abnormalities associated
with airflow limitation, it may provide a valuable clinical
test to help assess the presence and control of asthma
that is easier to perform than spirometry.
Methods
Subjects
Participants were recruited by advertisement. Asthmatic
participants (n = 35) had a clinical diagnosis of asthma
and were taking inhaled bronchodilator. Nonasthmatic
subjects (n = 34) denied any history of respiratory symp-
toms or diagnoses. Participants in both groups were
required to have less than 10 pack-years of tobacco
smoking. In a substudy to determine the height depen-
dence of resistance measurements, we recruited 84 addi-
tional nonasthmatic participants who denied smoking,
occupational exposure to smoke or dust, respiratory
symptoms, and any respiratory disease history. All sub-
jects provided informed consent, and this research was
conducted in compliance with the Helsinki Declaration.
This study was approved by Boston University Medical
Center IRB, Protocol H-25546, and Boston University
Charles River Campus IRB, File 1765E.
Experimental Protocol
Asthmatic subjects withheld short- and long-acting
bronchodilators 6 and 24 hours, respectively, prior to
study visits. All subjects attended two test days at least
24 hours apart. On day 1, the forced oscillation system
described below was used to measure end-inspiratory
Rrs during tidal breathing and Rmin at maximum inspira-
tion. Subjects took six tidal breaths followed by a slow
maximum inspiration followed by a passive exhalation
and six more tidal breaths. The procedure was repeated.
Subjects then performed spirometry. After baseline stu-
dies, subjects inhaled two inhalations of albuterol
metered-dose inhaler 90 μg/inhalation via spacer. Forced
oscillation and spirometry measurements were repeated
after 10 minutes.
O nd a y2 ,b a s e l i n em e a s u r e m e n t so fR min and spiro-
metry were obtained, followed by methacholine chal-
lenge. Methacholine (Provocholine
® ,M e t h a p h a r m ,
Canada) was administered in the following concentra-
tions: 0.098, 0.195, 0.391, 0.781, 1.563, 3.215, 6.25, 12.5,
and 25 mg/ml. Other than this concentration schedule,
testing was performed in accordance with current ATS
recommendations using the 5-breath dosimeter protocol
[5] using equipment described below. At the conclusion
o ft h ec h a l l e n g e( i . e .w h e na2 0 %d e c l i n ei nF E V 1
occurred or after the final dose of 25 mg/ml, whichever
came first), Rmin was measured again, and then 2 inhala-
tions of albuterol were administered. Spirometry and
Rmin measurements were repeated 10 minutes after
albuterol administration.
In the sample of nonasthmatics studied to establish
the relationship of Rmin to height, only Rmin and height
were measured.
Measurement of Rrs
We measured Rrs as previously described [4]. Briefly, a
12-in diameter subwoofer delivers an 8 Hz oscillation,
with amplitude of ± 1 cmH20, superimposed on sponta-
neous breathing. Jensen and co-workers [2] showed that
because soft-tissue is viscoelastic, it has a tissue resis-
tance that decreases hyperbolically with frequency and
that by 8 Hz the lung tissue resistance is negligible and
the chest-wall tissue resistance is at its minimum. A
three-way valve allows the subject to breathe fresh air
through a high-inertance tube. Flow at the airway open-
ing is measured by a pneumotachograph (4700 Series,
Hans Rudolph, Kansas City, MO) connected to a differ-
ential pressure transducer (ATD02AS, SCIREQ, Mon-
treal, QC). Pressure at the airway opening is recorded
with a differential pressure transducer (ATD5050,
S C I R E Q ) .T h e s ep r e s s u r ea n df l o ws i g n a l sa r et r a n s -
mitted through demodulator circuits and then to a 10
Hz low-pass filter (S/N 980987, SCIREQ). The filtered
signals are sampled at 40 Hz and stored digitally by Lab-
View (National Instruments, Austin, TX). Pressure and
flow data were separately low- and high-passed filtered
using Matlab software (Natick, MA) at a cut-off
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recursive least squares algorithm, described previously
[2], to estimate Rrs eight times per second. Minimum
airway resistance, Rmin,w a sd e r i v e da sR rs at maximum
inspiration.
The system used in the substudy of nonasthmatic sub-
jects (n = 84) conducted to determine normative pre-
dicted values for Rmin differed only in its differential
pressure transducers (Model LCRV, CELESCO, Chats-
worth, CA) and had a 1% error from the system used in
the main study.
Spirometry and methacholine challenge methods
Spirometry measurements were made with an integrated
spirometer-dosimeter system (KoKoDigidoser
® spirom-
eter, Ferraris Respiratory, Louisville, CO) using the DeV-
ilbiss 646 nebulizer. Our measured nebulizer output was
8.7 ± 0.8 uL/breath (mean ± SE), very close to that
reported in the literature for this equipment[6]. Pre-
dicted values for spirometric indices were based on pub-
lished regression equations [7]. Spirometry was
performed in accordance with published standards [8].
For methacholine challenges, interpolation was used to
calculate the provocative concentration causing a 20%
drop in FEV1 (PC20). We also calculated the methacho-
line dose-response slope [9] as a two-point slope of a
line connecting the first and last point of the dose-
response curve, measured in units of % decline from
baseline FEV1 per mg/mL of methacholine, an approach
that permits analysis of methacholine responsiveness as
a continuous measure even in subjects not experiencing
a 20% decline in FEV1. For logarithmic transformation
of dose-response slope prior to graphic display and cor-
relation analysis, the constant 0.1 was first added to deal
with zero or slightly negative values.
Data Analysis
Among subjects that denied asthma, those with a PC20
greater than 25 mg/mL were defined as “nonasthmatic
methacholine nonresponders.” Among subjects that
reported asthma, those with a PC20 ≤25 mg/mL were
defined as “asthmatic methacholine responders.”
A second-order linear regression analysis, using the
bisquare method[10] to account for undue influence of
outliers, was performed to derive a prediction equation
for Rmin b a s e do nh e i g h t ,u s i n gd a t af r o m8 4n o n a s t h -
matic substudy participants and 26 of the 34 nonasth-
matic participants in the full study who had a PC20 ≥25
mg/ml. Predicted values calculated with this equation
were used to derive Rmin % predicted = (measured Rmin
/predicted Rmin) * 100.
Statistical comparisons were made using paired or
unpaired t-tests, or a Mann-Whitney Rank Sum test if a
test of normality or equal variance failed, with a
significance level of 0.05. Correlations were examined
using the Pearson correlation coefficient. For subjects
that did not experience a 20% or greater decline in
FEV1 by the highest concentration of 25 mg/mL, we
assigned a PC20 value of 25 mg/mL so that we could
calculate a geometric mean for Table 1 (Subject
characteristics).
Receiver operator characteristic (ROC) curves to
examine the ability of Rmin % predicted and other para-
meters to predict airway hyperresponsiveness (defined as
aP C 20 < 16 mg/mL) were created by plotting sensitivity
(true positive rate) versus 1-specificity (true negative
rate), for each value of the test. The best threshold for
any test is that which maximizes sensitivity while mini-
mizing the false positive rate, represented by the left
upper most value on the curve. The area under the
curve (AUC) represents a measure of test accuracy
(AUC of 1.0 indicates perfect prediction; AUC of 0.50
indicates prediction no better than chance) and was cal-
culated via numerical integration.
Results
Subject Characteristics
We studied 34 nonasthmatic and 35 asthmatic partici-
pants with similar demographic and anthropomorphic
characteristics (Table 1). Only two of these subjects
(both nonasthmatics) were current tobacco smokers.
Asthmatics had lower spirometric indices and greater
methacholine responsiveness than nonasthmatics.
Among the 34 nonasthmatic subjects, 26 were classified
as “nonasthmatic methacholine nonresponders” as
defined above. Among the 35 subjects that reported
asthma, 31 subjects were classified as “asthmatic metha-
choline responders” as defined above. The 84 additional
Table 1 Characteristics* of 34 nonasthmatic and 35
asthmatic participants
Nonasthmatic
(n = 34)
Asthmatic
(n = 35)
Sex 22 F/12 M 22 F/13 M
Age (yr) 21 ± 2 21 ± 3
Height (cm) 170 ± 10 168 ± 10
Weight (kg) 65 ± 13 66 ± 12
FEV1 (% predicted) 95 ± 10
† 88 ± 11
FEV1/FVC (% predicted) 100 ± 7
† 90 ± 9
PC20 (mg/ml) 19 ± 2
†
median: 25
1.8 ± 5.2
median: 1.3
≥ 25 26 4
16 - 24.9 1 0
8 - 15.9 4 5
<8 3 2 6
* Mean ± standard deviation is shown for continuous variables, except for
PC20, which is geometric mean ± standard deviation.
† p < 0.05.
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oscillation and anthropomorphic measurements, had a
mean age of 21 and were 55% males.
Dynamic Rrs tracings and determination of Rmin in
representative subjects
Typical tracings of Rrs a n dr e l a t i v ev o l u m ef o ran o n -
asthmatic and an asthmatic subject are shown in Fig-
ure 1. For the asthmatic participant shown, the mean
end-inspiratory pre-deep inspiration Rrs was 2.36
cmH20/L/s, and Rmin was 1.46 cmH20/L/s, values
approximately 50% higher than those of the nonasth-
matic subject shown (1.45 and 0.99 cmH20/L/s for Rrs
and Rmin, respectively).
Relationship Between Rmin and Height
We examined the relationship between Rmin and height
among the 84 subjects that underwent limited testing
plus the 26 nonasthmatic methacholine nonresponders
in the full study. These two groups displayed a similar
relationship between Rmin and height (Figure 2) and
were therefore analyzed together. Regression analysis of
these 100 subjects revealed the following relationship:
Rmin =7 . 2 0− 5.46 ∗ Height + 1.07 ∗ Height2.
The R
2 for this model (regression line superimposed
on Figure 2) was 0.60, indicating a relationship between
Rmin and height of similar strength to that between
spirometric measurements and height [7]. Rmin was not
significantly related to sex or body-mass index after
accounting for height.
Rmin % predicted as an indicator of asthma and airway
hyperresponsiveness
The baseline Rrs (end-inspiration values averaged over 6
pre-deep inspiration tidal breaths), Rmin,a n dR min %
predicted differed significantly between asthmatics and
nonasthmatics, as did spirometric indices (Table 2).
These differences were even more pronounced when
comparing nonasthmatic methacholine nonresponders
and asthmatic methacholine responders (Table 2). The
Rmin % predicted was significantly greater among asth-
matics than nonasthmatics in all conditions (baseline,
post-albuterol, post-methacholine), differences that were
even more pronounced when comparing asthmatics to
nonasthmatic methacholine nonresponders (Figure 3).
Among subjects without asthma, the Rmin was greater
among those with a PC20 ≤25 mg/mL than among those
with a PC20 > 25 mg/mL (Rmin % predicted 131.7 +/-
5.3 SE vs. 102.1 +/- 2.9 SE, P < 0.0001).
Figure 1 Typical respiratory system resistance tracings for a nonasthmatic and an asthmatic subject. Typical trace of respiratory system
resistance (Rrs) at 8 Hz and relative inhaled volume (above functional residual volume) for a nonasthmatic (H09) and asthmatic (A04) subject at
baseline. Both participants are female and of similar age, height, and weight. End-inspiration Rrs values are used in analysis (open circles). The
minimum resistance achieved at maximum inspiration is termed Rmin. The Rrs is plotted as a solid line, and the inhaled volume is plotted as a
dotted line.
Mendonça et al. Respiratory Research 2011, 12:96
http://respiratory-research.com/content/12/1/96
Page 4 of 8In Figures 4, 5, 6, the methacholine dose-response
slope is plotted versus Rmin % predicted (Figure 4), FEV1
% predicted (Figure 5), and FEF25-75 % predicted (Figure
6) for nonasthmatic (closed circles) and asthmatic (open
triangle) participants. These plots reveal that the log10
dose-response slope was significantly correlated with
Rmin % predicted (r = 0.50, p < 0.0001), FEV1 %p r e -
dicted (r = -0.40, p < 0.001), and FEF25-75 % predicted
(r = -0.63, p < 0.00001). Defining airway hyperresponsive-
ness as a methcholine PC20 < 16 mg/mL (corresponding
to a dose-response slope > 1.2), 80% of the subjects with
baseline Rmin < 100% predicted did not have airway
hyperresponsiveness, while 100% of subjects with Rmin >
145% predicted had hyperresponsiveness, regardless of
clinical classification as asthmatic or nonasthmatic.
ROC curves were used to formally compare the ability
of these measurements to distinguish hyperresponsive
subjects (defined as PC20 less than 16 mg/ml) from sub-
jects without hyppresponsiveness and to identify the
optimal threshold levels for distinguishing these groups
(Figure 7). The thresholds yielding the highest combined
Table 2 Baseline physiologic measurements* in asthmatic and control subjects and in subgroups of these subjects
All
subjects
Subgroups
Physiologic
measurement
Nonasthmatic
(n = 34)
Asthmatic
(n = 35)
P value Nonasthmatic methacholine
nonresponders
(n = 26)
Asthmatic methacholine
responders
(n = 31)
P value
FEV1
% predicted
95 ± 10 88 ± 11 0.009 97 ± 8 88 ± 11 0.002
FEV1/FVC
% predicted
100 ± 7 90 ± 9 <
0.0001
102 ± 6 90 ± 9 <
0.0001
FEF25-75
% predicted
93 ± 20 69 ± 20 <
0.0001
99 ±18 68 ±18 <
0.0001
Rrs,
cmH20/L/s
2.21 ± 0.48 2.91 ± 0.99 0.0006 2.10 ±0.24 2.95 ±1.04 0.0005
Rmin,
cmH20/L/s
1.12 ± 0.31 1.39 ± 0.41 0.004 1.02 ± 0.24 1.41 ± 0.42 0.0001
Rmin,
% predicted
109 ± 19 134 ± 33 0.0004 102 ± 14 137 ± 33 <
0.0001
* Mean ± standard deviation.
Base   Post-alb         Base   Post-mch  Post-alb
        Day 1                           Day 2
R
m
i
n
 
%
 
p
r
e
d
0
50
100
150
200
250
300
Nonasthmatic
Nonasthmatic nonreactive
Asthmatic
*
*
*
**
*
*
*
*
*
Figure 3 Plot of Rmin % predicted for asthmatic and
nonasthmatic subjects.R min %predicted for all 34 nonasthmatic
(black) and 35 asthmatic (hatched) participants as well as the
subgroup of 26 nonasthmatic methacholine nonresponders (gray).
*indicates significant difference from asthmatic group in each
condition (p < 0.05)
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Figure 2 Plot of Rmin versus height for nonasthmatic subjects.
Rmin (cmH2O/L/s) is plotted by height (m) for 100 nonasthmatic
subjects, including 84 subjects recruited for limited testing (+) and
26 nonasthmatic methacholine nonresponders (0), as described in
the text. The superimposed regression line is derived from a second
order linear regression (r
2 = 0.60).
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91 for FEV1 % predicted, and 82 for FEF25-75 %p r e -
dicted. The AUC for Rmin,F E V 1,a n dF E F 25-75,w e r e
0.85, 0.78, and 0.87, respectively. The AUC for both the
FEV1/FVC ratio and FEF25-75/FVC ratio (not shown in
figure) was 0.81. The percent increase in FEV1 following
albuterol administration on the first day of the protocol
was also analyzed and was comparable to Rmin %p r e -
dicted (AUC = 0.85 with a threshold of 3.7% FEV1
increase). ROC curves were also calculated for hyperre-
sponsiveness defined as a PC20 <2 5m g / m l ,a n di nt h i s
case the Rmin % predicted had the highest AUC at 0.87.
Discussion
Our goal was to test the hypothesis that the minimal air-
w a yr e s i s t a n c ea c h i e v a b l ed uring a maximal inspiration
(Rmin) is abnormally elevated in subjects with airway
hyperresponsiveness. The breathing maneuver required
to measure Rmin by the forced oscillation method is less
burdensome and less subject to performance-related
errors than is spirometry. We observed that the baseline
Rmin, as a percent predicted value based on height, identi-
fies people with airway hyperresponsiveness approxi-
mately as well as FEF25-75 and slightly better than FEV1.
Previous reports suggested a decreased ability of asth-
matic airways to dilate in response to a deep inspiration,
a deficiency that was accentuated after bronchial chal-
lenge [2,11] Our measurements in a larger sample of
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Figure 4 Plot of methacholine dose-response slope versus Rmin
percent predicted. Scatter plot of dose-response slope versus
baseline Rmin % predicted for nonasthmatic (closed circles) and
asthmatic (open triangle) participants.
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Figure 5 Plot of methacholine dose-response slope versus FEV1
percent predicted. Scatter plot of dose-response slope versus FEV1
% predicted for nonasthmatic (closed circles) and asthmatic (open
triangle) participants.
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Figure 6 Plot of methacholine dose-response slope versus
FEF25-75 percent predicted. Scatter plot of dose-response slope
versus FEF25-75 % predicted for nonasthmatic (closed circles) and
asthmatic (open triangle) participants.
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Figure 7 Receiver operator characteristic curves for Rmin, FEV1,
and FEF25-75 as predictors of airway hyperreactvitiy. Receiver
operator characteristic (ROC) curves for Rmin, FEV1, and FEF25-75 as
predictors of airway hyperresponsiveness (PC20 < 16 mg/ml). The
thresholds yielding the highest combined sensitivity and specificity
were 115, 91, and 82 for Rmin % predicted, FEV1 % predicted, and
FEF25-75 % predicted, respectively. The area under the curve (AUC)
was 0.85, 0.78, and 0.87 for Rmin % predicted, FEV1 % predicted, and
FEF25-75 % predicted, respectively.
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line, Rmin, an inverse measure of airway caliber, was sig-
nificantly higher in asthmatics compared to
nonasthmatics. Following inhalation of albuterol, sub-
jects with asthma still had higher Rmin than nonasth-
matics (Figure 3). In fact, asthmatic subjects had a
higher mean Rmin after albuterol than the nonasthmatic
methacholine nonresponder group before albuterol (not
shown), indicating that in subjects with asthma, albu-
terol cannot always dilate airways to levels achievable in
nonasthmatic airways. This suggests that either albuterol
does not relax the airway smooth muscle of asthmatics
to the same extent as nonasthmatics or that the airway
walls have become stiff or narrowed by other mechan-
isms. In that our data on response to albuterol suggest
that asthmatics have an approximately similar decline in
Rmin in response albuterol as nonasthmatics (reduction
in Rmin % predicted 17 ± 6.3 SE vs. 11 ± 2.2 SE for asth-
matics and nonasthmatics, respectively; p = 0.38), this
may favor the explanation of residual differences in the
airway wall independent of ASM tone. It must be noted
that the dose of albuterol administered in our protocol,
i.e. 180 ug (two inhalations), is not a maximally bronch-
odilating dose. When the stiffer asthmatic airway is con-
stricted by methacholine, the inability to dilate with a
deep inspiration is exaggerated compared to nonasth-
matic participants, the Rmin % predicted increasing in
response to methacholine by 85 ± 12 SE vs. 38 ± 5.6 SE
(p < 0.001) in asthmatics and nonasthmatics, respec-
tively (Figure 3).
There are several factors that influence airway caliber,
including airway smooth muscle tone and stiffness, the
passive properties of the airway wall (e.g. airway wall
thickening), parenchymal tethering and transmural pres-
sure acting to distend the airway. Several of these can
be influenced by airway wall remodeling. Direct mea-
surement of airway distensibility in the intact lung (i.e.
the relationship between airway caliber and airway dis-
tending pressure) is difficult. Recent work by Brown et
al. confirms the ability to indirectly assess airway disten-
sibility non-invasively using forced oscillations [12,13].
Specifically, distensibility was quantified as the linear
slope of respiratory system conductance (1/Rrs)a n d
volume between 75% and 100% of total lung capacity.
This slope was decreased in asthmatics and unaffected
by reduction of bronchomotor tone with albuterol.
Brown et al. concluded that reduced airway distensibility
in asthmatics is consistent with structural changes asso-
ciated with airway wall remodeling and is not reflective
of increased airway smooth muscle tone. This is consis-
tent with the data of our study. Another key determi-
nant of the ability to dilate could be lung elastic recoil
pressure; past studies have reported a significant loss of
recoil in moderate-to-severe though perhaps not mild
asthma[14-16]. We did not measure elastic recoil in our
study and can only speculate on its role.
Several limitations of our study must be recognized.
The sample size was relatively small (n = 69 for the full
protocol and n = 84 for the limited testing to establish
predicted values for Rmin), the age range was limited to
to 18-29 years, and most subjects were Caucasian race.
A larger and more diverse sample would permit better
evaluation of the potential relationship of Rmin to age
and race, as well as subgroup analyses. In addition, the
asthmatic subjects had mild to moderate disease, so the
full spectrum of asthma was not reflected in our sample,
and we were not able to assess the correlation of Rmin
with clinical status. It is possible that there could be
important differences in the physiology of milder versus
more severe asthma. Finally, the deep inhalations per-
formed during the dosimeter protocol for methacholine
challenge have been reported to result in bronchopro-
tection and falsely negative challenge results among
mild asthmatics, compared to the tidal breathing proto-
col[17,18]. It would be of interest to have data on the
relationship of Rmin to airway responsiveness assessed by
both protocols.
Conclusions
Our study reveals that after adjusting for height, Rmin
differs between asthmatics and nonasthmatics, predicts
methacholine responsiveness, increases with administra-
tion of methacholine, and decreases with albuterol.
Compared to spirometry, this test requires less patient
effort and is easier for a technician or clinic staff mem-
ber to administer with technically acceptable results. In
conjunction with symptom history, Rmin could provide a
clinically useful tool for assessing asthma control and
monitoring the response to treatment. Longitudinal stu-
dies are needed to assess the utility of Rmin as an indica-
tor of asthma control and response to asthma therapy.
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